III期-话题@MedSci

#III期#

681篇内容 | 3331人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594547, encodeId=6c54159454eea, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Supernus报告了实验性注意力缺陷多动障碍药物SPN-812的III期阳性结果, objectType=article, longId=156436, objectId=7b8115643622, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b8115643622, replyNumber=0, likeNumber=99, createdTime=2018-12-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b8115643622, moduleTitle=Supernus报告了实验性注意力缺陷多动障碍药物SPN-812的III期阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b8115643622)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594546, encodeId=5bde1594546f0, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, objectType=article, longId=156414, objectId=bb9a156414cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb9a156414cc, replyNumber=0, likeNumber=37, createdTime=2018-12-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb9a156414cc, moduleTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb9a156414cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594545, encodeId=6c951594545a3, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, objectType=article, longId=156388, objectId=8ee71563888f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ee71563888f, replyNumber=0, likeNumber=79, createdTime=2018-12-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ee71563888f, moduleTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ee71563888f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594544, encodeId=d179159454471, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM：Durvalumab可显著延长III期无法切除的非小细胞肺癌患者总生存期, objectType=article, longId=155723, objectId=f948155e2338, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f948155e2338, replyNumber=0, likeNumber=96, createdTime=2018-12-15, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f948155e2338, moduleTitle=NEJM：Durvalumab可显著延长III期无法切除的非小细胞肺癌患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f948155e2338)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594543, encodeId=8fcb159454311, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=ALK阳性肺癌全新III期临床研究成果, objectType=article, longId=154858, objectId=84b91548588d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84b91548588d, replyNumber=0, likeNumber=66, createdTime=2018-12-02, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84b91548588d, moduleTitle=ALK阳性肺癌全新III期临床研究成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84b91548588d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594542, encodeId=168b1594542d0, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Vertex制药表示VX-659三联疗法治疗囊肿性纤维化的III期研究达到了主要终点, objectType=article, longId=154586, objectId=9b231545869e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b231545869e, replyNumber=0, likeNumber=73, createdTime=2018-11-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b231545869e, moduleTitle=Vertex制药表示VX-659三联疗法治疗囊肿性纤维化的III期研究达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b231545869e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594541, encodeId=d62e15945419f, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=DCR：I期至III期结肠癌根治术后低氯血症对于预后的影响, objectType=article, longId=153691, objectId=8475153691cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8475153691cc, replyNumber=0, likeNumber=68, createdTime=2018-11-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8475153691cc, moduleTitle=DCR：I期至III期结肠癌根治术后低氯血症对于预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8475153691cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594540, encodeId=85561594540a4, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=DCR：肛门上皮内瘤变III期的患者患肛门癌的风险因素, objectType=article, longId=153690, objectId=30ee1536902c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30ee1536902c, replyNumber=0, likeNumber=62, createdTime=2018-11-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30ee1536902c, moduleTitle=DCR：肛门上皮内瘤变III期的患者患肛门癌的风险因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30ee1536902c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594539, encodeId=2aac15945399d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%, objectType=article, longId=151769, objectId=5ffc151e69a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ffc151e69a2, replyNumber=0, likeNumber=77, createdTime=2018-10-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ffc151e69a2, moduleTitle=NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ffc151e69a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594538, encodeId=07cc15945381d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=2018年WCLC：Durvalumab有助于维持无法切除的III期非小细胞肺癌的PFS, objectType=article, longId=149831, objectId=c67914983121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c67914983121, replyNumber=0, likeNumber=55, createdTime=2018-09-29, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c67914983121, moduleTitle=2018年WCLC：Durvalumab有助于维持无法切除的III期非小细胞肺癌的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c67914983121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594537, encodeId=43d6159453edd, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM：Durvalumab可显著延长III期非小细胞肺癌患者总生存期, objectType=article, longId=149667, objectId=310b14966e82, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=310b14966e82, replyNumber=0, likeNumber=105, createdTime=2018-09-28, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=310b14966e82, moduleTitle=NEJM：Durvalumab可显著延长III期非小细胞肺癌患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=310b14966e82)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594536, encodeId=51ad1594536bd, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率, objectType=article, longId=149631, objectId=33901496318e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33901496318e, replyNumber=0, likeNumber=29, createdTime=2018-09-27, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33901496318e, moduleTitle=III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33901496318e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594535, encodeId=02491594535d8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Actelion门脉高压症新药Opsumit在III期临床研究中显示出良好前景, objectType=article, longId=149146, objectId=06fb149146c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06fb149146c6, replyNumber=0, likeNumber=61, createdTime=2018-09-21, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06fb149146c6, moduleTitle=Actelion门脉高压症新药Opsumit在III期临床研究中显示出良好前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06fb149146c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594534, encodeId=412a1594534f4, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=BORA III期延展试验证明阿斯利康IL-5单抗Fasenra对严重哮喘具有长期疗效, objectType=article, longId=149082, objectId=636f14908287, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=636f14908287, replyNumber=0, likeNumber=64, createdTime=2018-09-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=636f14908287, moduleTitle=BORA III期延展试验证明阿斯利康IL-5单抗Fasenra对严重哮喘具有长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=636f14908287)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594533, encodeId=b9e8159453362, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性, objectType=article, longId=149073, objectId=52291490e33c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52291490e33c, replyNumber=0, likeNumber=47, createdTime=2018-09-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52291490e33c, moduleTitle=III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52291490e33c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594532, encodeId=4c751594532d0, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=每月注射一次的长效HIV疗法cabotegravir/rilpivirine III期临床实验喜获成功, objectType=article, longId=146747, objectId=d9eb146e4766, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9eb146e4766, replyNumber=0, likeNumber=69, createdTime=2018-08-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9eb146e4766, moduleTitle=每月注射一次的长效HIV疗法cabotegravir/rilpivirine III期临床实验喜获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9eb146e4766)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594531, encodeId=fc95159453195, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=柳叶刀公布了Kyowa Kirin公司CCR4单抗Poteligeo 治疗皮肤T细胞淋巴瘤的III期临床数据, objectType=article, longId=146735, objectId=31ee146e35d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31ee146e35d9, replyNumber=0, likeNumber=89, createdTime=2018-08-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31ee146e35d9, moduleTitle=柳叶刀公布了Kyowa Kirin公司CCR4单抗Poteligeo 治疗皮肤T细胞淋巴瘤的III期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31ee146e35d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594530, encodeId=b6a71594530fc, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=III期临床TOLEDO研究显示阿扑吗啡可有效缓解帕金森病（PD）患者的持续运动波动, objectType=article, longId=145966, objectId=6cc314596637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cc314596637, replyNumber=0, likeNumber=62, createdTime=2018-08-07, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cc314596637, moduleTitle=III期临床TOLEDO研究显示阿扑吗啡可有效缓解帕金森病（PD）患者的持续运动波动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cc314596637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594529, encodeId=c0f01594529d2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=OPKO公司完成生长激素缺乏患儿（hGH-CTP）的Somatrogon全球III期研究的入组, objectType=article, longId=145945, objectId=022514594548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=022514594548, replyNumber=0, likeNumber=69, createdTime=2018-08-07, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=022514594548, moduleTitle=OPKO公司完成生长激素缺乏患儿（hGH-CTP）的Somatrogon全球III期研究的入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=022514594548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594528, encodeId=23c2159452822, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=大冢制药的guadecitabine未达到一线治疗AML的III期研究的主要终点, objectType=article, longId=145679, objectId=d3dd1456e979, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3dd1456e979, replyNumber=0, likeNumber=73, createdTime=2018-08-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3dd1456e979, moduleTitle=大冢制药的guadecitabine未达到一线治疗AML的III期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3dd1456e979)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Supernus报告了实验性注意力缺陷多动障碍药物SPN-812的III期阳性结果

2018-12-24

智智灵药 (审核中...)

前往app查看评论内容

#III期#

"PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动

2018-12-24

智智灵药 (审核中...)

前往app查看评论内容

#III期#

"PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动

2018-12-23

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM：Durvalumab可显著延长III期无法切除的非小细胞肺癌患者总生存期

2018-12-15

智智灵药 (审核中...)

前往app查看评论内容

#III期#

ALK阳性肺癌全新III期临床研究成果

2018-12-02

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Vertex制药表示VX-659三联疗法治疗囊肿性纤维化的III期研究达到了主要终点

2018-11-30

智智灵药 (审核中...)

前往app查看评论内容

#III期#

DCR：I期至III期结肠癌根治术后低氯血症对于预后的影响

2018-11-18

智智灵药 (审核中...)

前往app查看评论内容

#III期#

DCR：肛门上皮内瘤变III期的患者患肛门癌的风险因素

2018-11-18

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%

2018-10-25

智智灵药 (审核中...)

前往app查看评论内容

#III期#

2018年WCLC：Durvalumab有助于维持无法切除的III期非小细胞肺癌的PFS

2018-09-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM：Durvalumab可显著延长III期非小细胞肺癌患者总生存期

2018-09-28

智智灵药 (审核中...)

前往app查看评论内容

#III期#

III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率

2018-09-27

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Actelion门脉高压症新药Opsumit在III期临床研究中显示出良好前景

2018-09-21

智智灵药 (审核中...)

前往app查看评论内容

#III期#

BORA III期延展试验证明阿斯利康IL-5单抗Fasenra对严重哮喘具有长期疗效

2018-09-20

智智灵药 (审核中...)

前往app查看评论内容

#III期#

III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性

2018-09-20

智智灵药 (审核中...)

前往app查看评论内容

#III期#

每月注射一次的长效HIV疗法cabotegravir/rilpivirine III期临床实验喜获成功

2018-08-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

柳叶刀公布了Kyowa Kirin公司CCR4单抗Poteligeo 治疗皮肤T细胞淋巴瘤的III期临床数据

2018-08-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

III期临床TOLEDO研究显示阿扑吗啡可有效缓解帕金森病（PD）患者的持续运动波动

2018-08-07

智智灵药 (审核中...)

前往app查看评论内容

#III期#

OPKO公司完成生长激素缺乏患儿（hGH-CTP）的Somatrogon全球III期研究的入组

2018-08-07

智智灵药 (审核中...)

前往app查看评论内容

#III期#

大冢制药的guadecitabine未达到一线治疗AML的III期研究的主要终点

2018-08-03

科室
- - 订阅+
  - 更多科室
工具
服务